Lates News

According to the AI Express of Every Economy, Huaxin Securities issued a research report on August 13, giving Ganli Pharmaceutical (603087.SH) a buy rating. The main reasons for the rating include: 1) impressive performance in the first half of 2025, with both volume and price rising domestically, and high growth in overseas markets; 2) orderly advancement of innovative product pipeline, with core products entering phase III clinical trials. (Daily Economic News)